Skip to content

Brain Stimulation and Hand Training in Children With Hemiparesis

Synergistic Effect of Combined Transcranial Direct Current Stimulation/Constraint Induced Movement Therapy in Children With Hemiparesis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02250092
Enrollment
20
Registered
2014-09-26
Start date
2014-12-31
Completion date
2017-07-10
Last updated
2020-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Hemiparesis

Keywords

Cerebral Palsy, Hemiparesis, Stroke, Non-Invasive Brain Stimulation, Transcranial Direct Current Stimulation, Constraint-Induced Movement Therapy, Diffusion Tensor Imaging, Congenital Hemiparesis, Bimanual Therapy

Brief summary

Hemiparetic cerebral palsy influences motor function in children during development and throughout their lifetime. The deficits one sees are the result both of the congenitally induced brain lesion and the subsequent plasticity that can impair function of the surviving neurons in the damaged brain. Many current treatments have limited influence on children's neurorecovery. Constraint-induced movement therapy (CIMT) involving constraining the unaffected limb to encourage use of the affected limb has shown promise, yet with new technology revealing the potential to directly influence the brain, there is an urgent need to study the synergy of combined techniques. Non-invasive brain stimulation (NIBS) as a direct neuromodulatory intervention has the potential to act synergistically with CIMT to influence neurorecovery. Combining behavioral therapies, constraint-induced movement therapy (CIMT), with a novel form of neuromodulation, transcranial direct current stimulation (tDCS), we investigated the influence of this intervention on improved motor outcomes in children with cerebral palsy. The study hypotheses surround the safety, feasibility and efficacy of combined CIMT and tDCS wherein those children who receive the combined intervention will reveal no major adverse events, yet improved hand function and cortical excitability. To Note: In addition to the combination of NIBS with CIMT, we also investigated the combination of NIBS with another form of motor intervention, bimanual, or two-handed, training. During bimanual training, children engage both hands in movements. The goal of bimanual training is to teach children how to most effectively use their hands cooperatively. During bimanual training, children play with games and toys that require the use of both hands. Children also practice activities of daily living that require the use of both hands, such as putting hair in a ponytail, tying shoes, and buttoning clothing. N=8 for this pilot study and no randomization. (Burke Medical Research Institute partnered with Columbia University and did a parallel pilot study. N=8 (PIs Friel and Gordon; Protocol BRC449)

Detailed description

We use single-pulse transcranial magnetic stimulation (TMS) to measure the location and strength of brain connections that control hand movements.

Interventions

DEVICETranscranial Direct Current Stimulation (tDCS)

10 tDCS/CIMT Sessions

DEVICEPlacebo Comparator

Sponsors

Cerebral Palsy International Research Foundation
CollaboratorOTHER
Foundation for Physical Therapy, Inc.
CollaboratorINDUSTRY
National Institutes of Health (NIH)
CollaboratorNIH
University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
8 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

1. Hemispheric Stroke or Periventricular Leukomalacia confirmed by most recent MRI or CT radiologic report with resultant congenital hemiparesis 2. ≥ 10 degrees of active motion at the metacarpophalangeal joint 3. Receptive language function to follow two-step commands as evidenced by performance on TOKEN test of intelligence 4. No evidence of seizure activity within the last 2 years 5. Presence of a motor evoked potential from at least the contralesional hemisphere if not both hemispheres 6. Ages 8-21 years 7. Able to give informed assent along with the informed consent of the legal guardian 8. Children who have had surgeries, which may influence motor function eg- tendon transfer, will be included, yet surgical history will be documented and included in any publication within a participant characteristics table.

Exclusion criteria

1. Metabolic Disorders 2. Neoplasm 3. Epilepsy 4. Disorders of Cellular Migration and Proliferation 5. Acquired Traumatic Brain Injury 6. Pregnancy 7. Indwelling metal or incompatible medical devices 8. Evidence of skin disease or skin abnormalities 9. Botulinum toxin or Phenol block within \[six-months\] preceding the study

Design outcomes

Primary

MeasureTime frameDescription
Change in Assisting Hand Assessment (AHA)2 weeks, 6 monthsParticipants were videotaped while performing a bimanual age-appropriate activity. Investigators scored this performance using the Assessment of Assisting Hand (AHA) inventory. The AHA consists of 22 items, each scored on a 4-point scale. Raw scores are a sum of the 22 item scores, ranging from 22-88. Computer software logarithmically transforms ordinal raw scores into a final score. Final scores are reported on a logit-based AHA-unit scale and range from 0 to 100, with higher scores indicating greater ability. Outcome is reported as the change from baseline to 2 weeks and change from baseline to 6 months.

Secondary

MeasureTime frameDescription
Change in Canadian Occupational Performance Measurement (COPM)2 weeks, 6 monthsThe COPM is clinician-administered semi-structured interview measuring the participant's perception of satisfaction and performance of personally set goals. There are 3 categories (Self-Care, Productivity, and Leisure) each containing 3 subcategories each for a total of 9 items, which are rated on an ordinal scale from 1 (minimum importance) to 10 (maximum importance). Each of the child's goals are given a satisfaction and performance rating. The average of the satisfaction ratings across all goals is reported as the average satisfaction score, ranging from 1 to 10, with higher scores indicating a better outcome. Outcome is reported as the change from baseline to 2 weeks and change from baseline to 6 months.

Other

MeasureTime frameDescription
Change in Subject Symptom Assessment (SSA) From 2 Weeks to 6 Months2 weeks, 6 monthsThe Subject Symptom Assessment (SSA) is a questionnaire of common side effects reported in the literature that is asked of the child undergoing non-invasive brain stimulation. This measure asks the child to rate if the symptom is present (yes or no) and if it is present, rate the severity using a 1 to 4 scale (1 indicates absent, 2=mild, 3=moderate, 4=severe). Lower values are better as they represent absent or mild symptoms. Outcome is reported as the change in symptom severity from 2 weeks of treatment to 6 months of treatment. This measure is not collected at baseline.

Countries

United States

Participant flow

Participants by arm

ArmCount
tDCS/CIMT
Intervention Group will receive 20 minutes of 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT. Transcranial Direct Current Stimulation (tDCS): 10 tDCS/CIMT Sessions
10
tDCS Sham/CIMT
Placebo Group will receive 20 minutes of sham 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT. Placebo Comparator
10
Total20

Baseline characteristics

CharacteristictDCS Sham/CIMTTotaltDCS/CIMT
Age, Categorical
<=18 years
8 Participants18 Participants10 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
2 Participants2 Participants0 Participants
Age, Continuous13.17 years
STANDARD_DEVIATION 5.08
12.7 years
STANDARD_DEVIATION 4.17
12.33 years
STANDARD_DEVIATION 3.08
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
10 Participants10 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants2 Participants2 Participants
Race (NIH/OMB)
White
0 Participants8 Participants8 Participants
Region of Enrollment
United States
10 participants20 participants10 participants
Sex: Female, Male
Female
6 Participants11 Participants5 Participants
Sex: Female, Male
Male
4 Participants9 Participants5 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 10
other
Total, other adverse events
10 / 1010 / 10
serious
Total, serious adverse events
0 / 100 / 10

Outcome results

Primary

Change in Assisting Hand Assessment (AHA)

Participants were videotaped while performing a bimanual age-appropriate activity. Investigators scored this performance using the Assessment of Assisting Hand (AHA) inventory. The AHA consists of 22 items, each scored on a 4-point scale. Raw scores are a sum of the 22 item scores, ranging from 22-88. Computer software logarithmically transforms ordinal raw scores into a final score. Final scores are reported on a logit-based AHA-unit scale and range from 0 to 100, with higher scores indicating greater ability. Outcome is reported as the change from baseline to 2 weeks and change from baseline to 6 months.

Time frame: 2 weeks, 6 months

ArmMeasureGroupValue (MEAN)
tDCS/CIMTChange in Assisting Hand Assessment (AHA)2 weeks6.4 score on a scale
tDCS/CIMTChange in Assisting Hand Assessment (AHA)6 months5.5 score on a scale
tDCS Sham/CIMTChange in Assisting Hand Assessment (AHA)2 weeks8 score on a scale
tDCS Sham/CIMTChange in Assisting Hand Assessment (AHA)6 months7.6 score on a scale
Secondary

Change in Canadian Occupational Performance Measurement (COPM)

The COPM is clinician-administered semi-structured interview measuring the participant's perception of satisfaction and performance of personally set goals. There are 3 categories (Self-Care, Productivity, and Leisure) each containing 3 subcategories each for a total of 9 items, which are rated on an ordinal scale from 1 (minimum importance) to 10 (maximum importance). Each of the child's goals are given a satisfaction and performance rating. The average of the satisfaction ratings across all goals is reported as the average satisfaction score, ranging from 1 to 10, with higher scores indicating a better outcome. Outcome is reported as the change from baseline to 2 weeks and change from baseline to 6 months.

Time frame: 2 weeks, 6 months

ArmMeasureGroupValue (MEAN)
tDCS/CIMTChange in Canadian Occupational Performance Measurement (COPM)2 weeks2.14 score on a scale
tDCS/CIMTChange in Canadian Occupational Performance Measurement (COPM)6 months2.94 score on a scale
tDCS Sham/CIMTChange in Canadian Occupational Performance Measurement (COPM)2 weeks1.8 score on a scale
tDCS Sham/CIMTChange in Canadian Occupational Performance Measurement (COPM)6 months3.22 score on a scale
Other Pre-specified

Change in Subject Symptom Assessment (SSA) From 2 Weeks to 6 Months

The Subject Symptom Assessment (SSA) is a questionnaire of common side effects reported in the literature that is asked of the child undergoing non-invasive brain stimulation. This measure asks the child to rate if the symptom is present (yes or no) and if it is present, rate the severity using a 1 to 4 scale (1 indicates absent, 2=mild, 3=moderate, 4=severe). Lower values are better as they represent absent or mild symptoms. Outcome is reported as the change in symptom severity from 2 weeks of treatment to 6 months of treatment. This measure is not collected at baseline.

Time frame: 2 weeks, 6 months

ArmMeasureValue (MEAN)
tDCS/CIMTChange in Subject Symptom Assessment (SSA) From 2 Weeks to 6 Months1.7 score on a scale
tDCS Sham/CIMTChange in Subject Symptom Assessment (SSA) From 2 Weeks to 6 Months1.76 score on a scale

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026